15 To 23 Amino Acid Residues In Defined Sequence Patents (Class 530/326)
-
Publication number: 20140005282Abstract: Specific peptides are provided, and derived ionization characteristics of those peptides, from the Hepatocyte Growth Factor Receptor (cMET) protein. The peptides are particularly and surprisingly advantageous for quantifying by the method of Selected Reaction Monitoring (SRM) mass spectrometry the cMET protein directly in biological samples that have been fixed in formalin, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including: formalin-fixed tissue/cells; formalin-fixed/paraffin embedded (FFPE) tissue/cells; FFPE tissue blocks and cells from those blocks; and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: December 27, 2011Publication date: January 2, 2014Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil
-
Publication number: 20140005117Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: ApplicationFiled: August 30, 2013Publication date: January 2, 2014Applicant: Morehouse School of MedicineInventors: Vincent Craig BOND, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
-
Publication number: 20140005096Abstract: Disclosed herein, in certain embodiments, are peptides for use in inhibiting the interactions of PF4 and RANTES. Further disclosed herein, are methods for treating an inflammatory disease, disorder, condition, or symptom. In some embodiments, the method comprises co-administering an agent that inhibits the interactions of PF4 and RANTES and a second active agent.Type: ApplicationFiled: July 15, 2013Publication date: January 2, 2014Applicant: Carolus Therapeutics, Inc.Inventors: Joshua Robert SCHULTZ, Benedikt VOLLRATH, Court TURNER
-
Publication number: 20140005358Abstract: This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.Type: ApplicationFiled: August 21, 2012Publication date: January 2, 2014Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Candace Y.W. Lee, John C. Burnett, Jr.
-
Publication number: 20140005120Abstract: An activity enhancer for an anticancer agent includes, as an active ingredient, a D-form amino acid residue-containing FNIII14 polypeptide, the D-form amino acid residue-containing FNIII14 being a polypeptide FNIII14 represented by SEQ ID NO: 1 in which at least one of amino acid residues at positions 1 to 13 is a D-form amino acid residue. An anticancer composition includes the activity enhancer for an anticancer agent and an anticancer agent.Type: ApplicationFiled: March 9, 2012Publication date: January 2, 2014Applicant: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Fumio Fukai, Hiroaki Kodama, Takuya Matsunaga
-
Publication number: 20140005118Abstract: The invention relates to ?-catenin targeting peptides comprising an a-helical segment that are optionally stapled or stitched, and pharmaceutical compositions thereof. Uses of the inventive ?-catenin targeting polypeptides including methods for treatment of disease, such as diseases associated with aberrant Wnt signaling, including cancer, are also provided.Type: ApplicationFiled: September 22, 2011Publication date: January 2, 2014Applicant: President and Fellows of Harvard CollegeInventors: Gregory L. Verdine, Tom N. Grossmann, Tsung-Han Johannes Yeh
-
Patent number: 8618046Abstract: The present invention relates to a method for treating atherosclerosis and/or atherosclerosis sequelae with a compound that includes FX8(F)oPX9HX10X11X12DX2X3X4X5X6X7 where X8 is G, A, F, Y or K, X9 is E, Y, A, Q, K or S, X10 is H, V, L, F or I, X11 is L, W, S, I, F or Y, X12 is V, T, F or I, X5 is S or Y, X6 is L, A or I, X7 is S, N or T, and o is 0 or 1.Type: GrantFiled: August 8, 2008Date of Patent: December 31, 2013Assignee: Affiris AGInventors: Sylvia Brunner, Petra Luehrs, Frank Mattner, Walter Schmidt, Barbara Wittmann
-
Patent number: 8618060Abstract: The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: GrantFiled: February 12, 2007Date of Patent: December 31, 2013Assignee: University of TasmaniaInventors: Vladimir Berezin, Elisabeth Bock, Milena Penkowa
-
Patent number: 8618055Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: GrantFiled: January 27, 2011Date of Patent: December 31, 2013Assignee: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Patent number: 8618248Abstract: The present invention relates to phosphopeptide compositions and anti-phosphopeptide antibody compositions. Also provided are methods of identifying phosphorylation sites in phosphorylated peptides and phosphorylation site motifs.Type: GrantFiled: October 30, 2007Date of Patent: December 31, 2013Assignee: President and Fellows of Harvard CollegeInventors: Steven P. Gygi, Judit Villen, Sean Beausoleil
-
Patent number: 8618062Abstract: There is disclosed agents capable of inhibiting the binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, and methods of modulating the activity of a cell utilizing the agents. The methods are particularly suitable for inhibiting the growth of cancer cells.Type: GrantFiled: January 12, 2012Date of Patent: December 31, 2013Assignee: Inter-K Pty LimitedInventors: Michael Valentine Agrez, Nuzhat Ahmed
-
Patent number: 8618066Abstract: Coating compositions having a peptidic antimicrobial additive and an antimicrobial additive of another configuration are provided. The concentrations of the antimicrobial agents within the coating composition are sufficient to synergistically inhibit microbial growth on an inanimate surface coated with the surface coating composition or within a container storing the coating composition. Methods for making and using such compositions to inhibit microbial growth in stored coatings and on susceptible surfaces are also provided.Type: GrantFiled: October 1, 2007Date of Patent: December 31, 2013Assignee: Reactive Surfaces, Ltd., LLPInventor: C. Steven McDaniel
-
Patent number: 8618043Abstract: This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions.Type: GrantFiled: April 5, 2011Date of Patent: December 31, 2013Assignee: Ramot at Tel-Aviv UniversityInventors: Illana Gozes, Roy N. Alcalay, Inna Divinski, Eliezer Giladi
-
Patent number: 8617560Abstract: The present invention relates to peptides or pretide derivatives of the 65kD lower matrix phosphoprotein of human cytomegalovirus. The peptides disclosed are useful for determining whether subjects have een exposed to human cytomegalovirus. Methods for using these peptides or derivatives thereof to determine the peptide-induced production of interferon-? and/or TNF-? in CD8+ T cells isolated from subjects are also disclosed.Type: GrantFiled: March 28, 2006Date of Patent: December 31, 2013Inventors: Florian Kern, Hans-Dieter Volk, Petra Reinke, Nicole Faulhaber, Ingolf-Pascal Surel, Elham Khatamzas
-
Publication number: 20130345138Abstract: The present invention is based, in part, on our discovery of compositions and methods that can be used to treat a patient who has a compromised bone (due, for example, to a disease such as osteoporosis or an injury such as a bone fracture). The compositions can also be administered prophylactically. For example, they can be administered to help maintain bone health as a patient ages. More specifically, the compositions include polypeptides that constitute (or that include) a fragment of a calcitonin receptor (CR) and polypeptides that constitute (or include) biologically active variants of those fragments. Sequence-specific formulas are provided herein, and polypeptides conforming to those formulas, as well as nucleic acids encoding them, expression vectors, host cells, pharmaceutical formulations, and methods of their preparation and use are within the scope of the present invention.Type: ApplicationFiled: December 7, 2011Publication date: December 26, 2013Applicant: The Research Foundation of State University of New YorkInventor: Srinivas Pentyala
-
Publication number: 20130345393Abstract: The purpose of the present invention is to provide a cross-linked peptide containing a novel non-peptide cross-linked structure, and a method for synthesizing the same. A cross-linked peptide having a novel non-peptide cross-linked structure, a useful intermediate for synthesizing the cross-linked peptide, and a method for synthesizing the novel cross-linked peptide and the intermediate are provided. The cross-linked peptide is characterized by having an —NR— bond in the cross-linked structure. By using the method for synthesizing the cross-linked peptide, a cross-link can be freely designed and an change can be freely made to a cross-link.Type: ApplicationFiled: February 28, 2012Publication date: December 26, 2013Applicant: JITSUBO Co., Ltd.Inventors: Yusuke Kono, Shuji Fujita, Hideaki Suzuki, Mari Okumoto, Takashi Nakae, Kazuhiro Chiba
-
Publication number: 20130344173Abstract: In certain embodiments transgenic plants (e.g., transgenic tomatoes) are provided that comprise cells that express a peptide one or more domains of which comprise the amino acid sequence of an apolipoprotein or apolipoprotein mimetic peptide where the peptide has biological activity (e.g., lowers SAA, and/or increases paroxonase activity, and/or improves HDL inflammatory index, etc.) when the plant and/or the peptide is fed to a mammal.Type: ApplicationFiled: March 7, 2013Publication date: December 26, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: ALAN M. FOGELMAN, SRINIVASA T. REDDY, MOHAMAD NAVAB
-
Publication number: 20130345135Abstract: The present invention provides for methods of treating and slowing the onset of heart failure. The inventors have determined that myosin binding to unphosphorylated Myosin Binding Protein C (MyBP-C) plays a key role in the diminution of cardiac contractile force and frequency in heart failure. The present invention provides peptide inhibitors of the MyBP-C/myosin interaction, thereby increasing both cardiac contractile force and frequency in the failing heart, as well as in patients not yet exhibiting frank heart failure.Type: ApplicationFiled: March 14, 2013Publication date: December 26, 2013Inventors: RICHARD L. MOSS, Ariel Fernandez
-
Publication number: 20130345119Abstract: The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use.Type: ApplicationFiled: December 28, 2010Publication date: December 26, 2013Applicants: INTELLIGENT SYNTHETIC BIOLOGY CENTER, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Sun-Chang Kim, Ju Ri Shin, Ki Jung Lim, Da Jung Kim, Young Woong Lee, Su A Jang, Bong Hyun Sung
-
Patent number: 8614291Abstract: The present invention is directed to absorbable polyesters comprising one or more monophosphate functionality; a conjugate comprising the foregoing polyester and a peptide and/or a bioactive agent; microparticles comprising an absorbable polyester; a conjugate comprising the microparticles and a peptide and/or a bioactive agent; an acylated or alkylated polysaccharide having one or more monophosphate functionality; a conjugate comprising the acylated or alkylated polysaccharide and a peptide and/or a bioactive agent; and pharmaceutical compositions thereof.Type: GrantFiled: January 27, 2006Date of Patent: December 24, 2013Assignee: Poly-Med, Inc.Inventors: Shalaby Wahba Shalaby, Joel Thomas Corbett
-
Patent number: 8613931Abstract: The present invention relates to the use of mimotopes in the treatment of diseases associated with ?-amyloid formation and/or aggregation (?-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to A?1-40/42, A?pE3-40/42, A?3-40/42 and A?11-40/42.Type: GrantFiled: June 12, 2009Date of Patent: December 24, 2013Assignee: Affiris AGInventors: Markus Mandler, Christian Gieffers, Frank Mattner, Andrea Dolischka, Oleksandr Otava
-
Publication number: 20130337050Abstract: A peptide, wherein the peptide comprises an amino acid sequence expressed by the following SEQ ID NO: 1, an amino acid sequence expressed by the following SEQ ID NO: 2, an amino acid sequence expressed by the following SEQ ID NO: 3, an amino acid sequence expressed by the following SEQ ID NO: 4, or any combination thereof: (SEQ?ID?NO:?1) ALGDSLYGAASLN; (SEQ?ID?NO:?2) MTVDNPASTTNKDKLFSVWK; (SEQ?ID?NO;?3) PGAVPEK; and (SEQ?ID?NO:?4) STKDLTTY.Type: ApplicationFiled: July 31, 2013Publication date: December 19, 2013Applicants: ImmunoFuture, Inc., Microbial Chemistry Research FoundationInventors: Akio NOMOTO, Coh-ichi NIHEI
-
Publication number: 20130337467Abstract: The invention provides the sequences of two polypeptides comprising the amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:2, which can be used for the preparation of monoclonal antibodies against human p28GANK. The invention also provides the monoclonal antibodies against human p28GANK and their use.Type: ApplicationFiled: December 9, 2011Publication date: December 19, 2013Applicant: The Second Military Medical University, The People's Liberation ArmyInventors: Hongyang Wang, Yao Chen, Jing Fu, Dongping Hu, Tao Luo, Liwei Dong
-
Publication number: 20130338338Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Applicants: COGNETIX, INC., THE UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Maren WATKINS, Baldomero M. OLIVERA, David R. HILLYARD, J. Michael McIntosh, Robert M. JONES
-
Publication number: 20130337557Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scleritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.Type: ApplicationFiled: October 14, 2010Publication date: December 19, 2013Applicant: XIGEN S.A.Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie
-
Publication number: 20130337028Abstract: The present invention relates to synthetic peptides for use in bone tissue repair and regeneration applications. The present invention also relates to various compositions and devices (including implantable orthopedic/dental devices) that contain the synthetic peptides of the present invention, and methods involving the use of the synthetic peptides of the present invention. The present invention also relates to a bone replacement or bone-reconstructive material, which includes a polymer matrix and a synthetic peptide of the present invention.Type: ApplicationFiled: June 22, 2011Publication date: December 19, 2013Applicant: NANOVIS, INC.Inventors: Ganesan Balasundaram, Matthew Hedrick
-
Publication number: 20130338075Abstract: The present invention generally relates to methods and compositions for preventing or treating axonal and/or neuronal degeneration in a subject by administering a composition comprising a peptide that comprises the amino acid sequence Arginine-Glycine-Aspartate (RGD).Type: ApplicationFiled: June 13, 2013Publication date: December 19, 2013Inventor: Thien Nguyen
-
Publication number: 20130337002Abstract: The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: ApplicationFiled: December 2, 2011Publication date: December 19, 2013Applicant: BIONOR IMMUNO ASInventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Jens Olof Holmberg, Birger Sørensen
-
Publication number: 20130338063Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.Type: ApplicationFiled: March 22, 2012Publication date: December 19, 2013Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Shalina Mahajan-Miklos, Li Jing Sun
-
Patent number: 8609409Abstract: The present invention provides a synthetic cell culture platform, comprising: a two dimensional and/or three dimensional surface comprising peptides conjugated to said surface and methods of using the platform for increasing cell adhesion, stable attachment and/or proliferation of cells grown on the platform and for promoting differentiation of neural stem cells into neurons.Type: GrantFiled: August 29, 2012Date of Patent: December 17, 2013Assignee: Clemson UniversityInventors: Xiaowei Li, Ning Zhang, Xuejun Wen
-
Patent number: 8609608Abstract: This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.Type: GrantFiled: March 24, 2010Date of Patent: December 17, 2013Assignees: C3 Jian, Inc., The Regents of the University of CaliforniaInventors: Jian He, Randal H. Eckert, Fengxia Qi, Maxwell H. Anderson, Wenyuan Shi
-
Patent number: 8609609Abstract: Host RNA/viral protein interaction as a target of intervention in the replication of viruses, e.g., the human immunodeficiency virus (HIV) are described. The target being upstream of the final replication product, and being crucial to the viral replication, is less likely to be genetically altered to drug resistance. Peptides that intervene in this RNA/viral protein interaction are also described, as well as compositions containing the same and methods of use thereof.Type: GrantFiled: January 16, 2009Date of Patent: December 17, 2013Assignee: North Carolina State UniversityInventor: Paul F. Agris
-
Patent number: 8609809Abstract: Novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are provided.Type: GrantFiled: January 19, 2010Date of Patent: December 17, 2013Assignee: Aileron Thraputics, Inc.Inventor: Huw M. Nash
-
Patent number: 8609105Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.Type: GrantFiled: March 18, 2009Date of Patent: December 17, 2013Assignee: Seattle Genetics, Inc.Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
-
Publication number: 20130330744Abstract: The present invention relates to the identification of a novel biomarker for cardiac ischemia: nitrated cardiac troponin I. The present invention also provides methods for the identification and use of a nitrated cardiac troponin as a biomarker for the diagnosis, prognosis and treatment management of myocardial ischemia, with and without necrosis of heart muscle. Diagnosis and prognosis is conducted by determining the amount of nitrated cardiac troponin I in serum samples of subjects and the ratio of nitrated cardiac troponin I to non-nitrated cardiac troponin I in serum samples of subjects. This biomarker can be detected by immunoassay techniques and tandem mass spectrometry. The present invention further relates to peptides, antibodies, compositions, methods, techniques, tests and kits for the identification and quantification of nitrated cardiac troponin I in samples of subjects.Type: ApplicationFiled: June 11, 2012Publication date: December 12, 2013Inventors: Gabriela Venturini Da Silva, Alexandre Da Costa Pereira, José Eduardo Krieger, Deborah Schetchman, Pedro Lemos, Jeane Mike Tsutsui, Valdemir Melechco Carvalho, Karina Helena Morais Cardozo
-
Publication number: 20130331333Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.Type: ApplicationFiled: December 29, 2011Publication date: December 12, 2013Applicant: Hadasit Medical Research Services and Development LimitedInventor: Rachel Bar-Shavit
-
Patent number: 8603977Abstract: The present invention relates to conformationally constrained parathyroid hormone (PTH) analogs, and methods of preparing and using the PTH analogs. The invention provides novel PTH polypeptide derivatives containing amino acid substitutions at selected positions in the polypeptides. The invention provides derivatives of PTH(1-34), PTH(1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11), and PTH(1-10) polypeptides, wherein at least one residue in each polypeptide is a helix, preferably an ?-helix, stabilizing residue. The invention also provides methods of making such peptides. Further, the invention encompasses compositions and methods for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g., in treating fractures or cartilage disorders and for raising cAMP levels in cells where deemed necessary.Type: GrantFiled: June 9, 2009Date of Patent: December 10, 2013Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Naoto Shimizu, Henry M. Kronenberg, John T. Potts, Jr.
-
Patent number: 8604165Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.Type: GrantFiled: June 25, 2008Date of Patent: December 10, 2013Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson
-
Patent number: 8604166Abstract: The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.Type: GrantFiled: September 2, 2009Date of Patent: December 10, 2013Assignees: Inserm (Institut National de la Sante et de la Recherche Medicale), Universite de Nantest, Chu NantesInventors: Nathalie Labarriere, Agnes Moreau-Aubry, Yann Godet
-
Publication number: 20130323283Abstract: Methods for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease in a subject in need thereof comprise administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of a histone/protein acetyltransferase (HAT). Methods for identifying an agent useful for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease comprise (a) contacting a candidate agent with a test sample comprising Foxp3+ T regulatory cells (Tregs), and (b) comparing a function of the Foxp3+ Tregs in the test sample with that in a control sample, wherein inhibition of the function of the Foxp3+ Tregs in the test sample when compared with the control sample indicates that the candidate agent is an agent useful for treating or preventing a Foxp3+ Treg related disease.Type: ApplicationFiled: December 1, 2011Publication date: December 5, 2013Applicants: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Wayne W. Hancock, Steven M. Albelda, Philip A. Cole
-
Publication number: 20130323272Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: June 28, 2013Publication date: December 5, 2013Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefanges, Toni Weinschenk, Peter Lewandrowski
-
Publication number: 20130323187Abstract: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.Type: ApplicationFiled: November 26, 2012Publication date: December 5, 2013Applicant: PARTNERSHIP & CORP. TECHNOLOGY TRANSFERInventors: Nicolas Fasel, Amal Kuendig
-
Publication number: 20130323171Abstract: Radiolabeled bombesin (BBN) analogs that bind to the gastrin-releasing peptide receptor (GRPR) represent a topic of active investigation for the development of molecular probes for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) of prostate cancer (PCa). RM1 and AMBA have been identified as the two most promising BBN peptides for GRPR-targeted cancer imaging and therapy. In this study, to develop a clinically translatable BBN-based PET probe, we synthesized and evaluated 18F—AlF- and 64Cu-radiolabeled RM1 and AMBA analogs for their potential application in PET imaging of PCa.Type: ApplicationFiled: June 5, 2013Publication date: December 5, 2013Inventors: Zhen Cheng, Hongguang Liu, Xiang Hu, Yang Liu
-
Patent number: 8598125Abstract: The present invention provides the peptide of (A) or (B) below, and methods of using the peptide: (A) a peptide including the amino acid sequence of SEQ ID NO: 1 or 2, (B) a peptide which includes the amino acid sequence of SEQ ID NO: 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows killer T cell-inducing activity.Type: GrantFiled: June 13, 2008Date of Patent: December 3, 2013Assignee: Onco Therapy Science, Inc.Inventors: Yasuharu Nishimura, Michiko Harao, Takuya Tsunoda, Yusuke Nakamura
-
Patent number: 8598314Abstract: Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.Type: GrantFiled: September 26, 2008Date of Patent: December 3, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Soumitra S. Ghosh, Josue Alfaro-Lopez, Lawrence J. D'Souza, Odile Esther Levy, Qing Lin, Christopher J. Soares
-
Patent number: 8598126Abstract: The present invention is concerned with means and methods for diagnosing or treating HPV associated neoplasia or tumors. Specifically, it relates to a peptide comprising an amino acid sequence motif as shown in SEQ ID No: 1. Moreover, contemplated by the present invention are fusion polypeptides, polynucleotides, vectors and host cells based on said peptide. Furthermore, the peptides, fusion polypeptides, polynucleotides, and vectors are suitable as pharmaceutical compositions for treating HPV associated neoplasia or tumors. The peptides and fusion polypeptides are also suitable as diagnostic compositions for diagnosing HPV associated neoplasia or tumors. The present invention also refers to a method of identifying a compound capable of binding to the HPV E6 protein. Finally, a kit is provided for carrying out the aforementioned diagnosis or compound identification.Type: GrantFiled: April 7, 2009Date of Patent: December 3, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des offentlichen RechtsInventors: Felix Hoppe-Seyler, Karin Hoppe-Seyler, Susanne Kintscher
-
Patent number: 8598315Abstract: This invention relates to novel protein transduction domains (PTDs) derived from secretory leukocyte protease inhibitor (SLPI). SLPI-derived PTDs are able to deliver cargo moieties in vivo and in vitro into the cytoplasm and nucleus of a host cell. The invention also relates to a transduction complex comprising one or more SLPI-derived PTDs linked or fused to one or more cargo moieties, which may comprise, for example, proteins, nucleic acids, lipids, carbohydrates, small molecules and other chemical compounds. The invention also relates to the manufacture of SLPI-derived PTDs, complexes comprising them; compositions comprising SLPI-derived PTDs or complexes; and utilization of SLPI-derived PTDs or complexes comprising them for therapeutic, diagnostic and research methods involving delivery of heterologous molecules across cellular membranes, and especially, across nuclear membranes.Type: GrantFiled: October 2, 2008Date of Patent: December 3, 2013Assignee: Research Foundation of City University of New YorkInventors: Marie T. Filbin, Sari S. Hannila
-
Publication number: 20130316380Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95.Type: ApplicationFiled: June 6, 2013Publication date: November 28, 2013Applicant: Laboratory Corporation of America HoldingsInventors: Jeff Sperinde, John William Winslow, Xueguang Jin
-
Publication number: 20130316378Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.Type: ApplicationFiled: April 15, 2013Publication date: November 28, 2013Applicant: OTAGO INNOVATION LIMITEDInventors: Christopher Joseph PEMBERTON, Arthur Mark RICHARDS, Michael Gary NICHOLLS, Timothy Grant YANDLE
-
Publication number: 20130316950Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: ApplicationFiled: December 12, 2011Publication date: November 28, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz